Open in interactive viewer → charts, metric popovers & call review

Crescent Capital BDC Stops Waiting for the Market and Starts Buying Its Own Discount

A $50M buyback, a $25M Sun Life backstop and a $150M seeded JV — the answer to a question CCAP spent two years deflecting
CCAP · Earnings Call · 2026-11-10

From "balanced approach" to buying back the discount

For at least two years, the most persistent question on Crescent Capital BDC's calls has been some version of: your stock trades at a gaping discount to net asset value — why are you recycling repayments into new loans instead of buying the shares? In February, Mickey Schleien of Clear Street asked it almost verbatim: “can you give us some background on the rationale for rotating proceeds from portfolio repayments into new investments instead of taking advantage of deep discount to NAV that the stock is offering?” — Mickey Schleien, Analyst · 2026-02-26 Henry Chung's answer was the house line — a “balanced approach here where we're still continuing to execute on our buyback plan” — Henry Chung, Chief Investment Officer · 2026-02-26 that nonetheless kept “maintaining the overall asset base and continuing to invest in new investments as they come through the pipeline.” — Henry Chung, Chief Investment Officer · 2026-02-26

That answer is now gone. On the third-quarter call management did not describe a balance; it described a sequence. Originnew origination activity has been deliberately throttled — gross deployment of just $24 million against $39 million of exits — while leverage is pushed back toward target and the freed capital is aimed squarely at the shares.

We believe our current share price materially undervalues CCAP, making repurchases at substantial discounts to NAV a compelling use of available capital.

Jason Breaux, Chief Executive Officer · 2026-11-10

The architecture is three-legged: a $50 million CCAP repurchase program, an additional $25 million of open-market purchases by parent Sun Life at the same NAV thresholds, and — the part that makes the first two executable — a new unconsolidated joint venture seeded with roughly $150 million of performing first-lien assets, in which CCAP will commit about $30 million of equity alongside a like-sized partner contribution, capitalized further with an ABL facility and targeting low-to-mid-teens ROE. It is a seed portfolio meant to be replenished, not a static pool that runs off, and Henry was explicit that it is not the first of many: “as we sit here today, we are not contemplating any further JVs in the near term.” — Henry Chung, Chief Investment Officer · 2026-11-10

Read the capital math and the urgency makes sense. Net assets were $653 million, or $17.72 per share, against a market capitalization near $382 million — a discount in the rough neighborhood of 40%. Against a full-history price series that peaked at $20.90 in October 2021 and has since drawn down more than 50%, and a 90-day tape that has given up another 6%, the arbitrage between NAV and price is the single largest return lever management controls.

The deleveraging that has to happen first

The buyback could not simply be switched on, because the balance sheet had drifted out. Debt-to-equity ended the quarter at 1.42x, or 1.36x net of cash, versus 1.37x net in the prior period — above the long-horizon leverage target range. The fundamentals confirm the direction of travel rather than a one-quarter blip: liabilities to assets stood at 59.5%, up 3.3 percentage points year over year and roughly 7 points higher than four years ago, and effective net cash was negative $888 million, essentially unchanged year over year — the borrowings never really came down.

So the JV is, functionally, a deleverage tool with a yield kicker. Jason Breaux was asked directly whether the mid-teens JV return could be an end in itself; he reframed it: “while it is accretive to the gross yield of the portfolio as a whole, the rationale for the JV and the formation of the JV is really focused on those 2 former strategic goals of ours.” — Jason Breaux, Chief Executive Officer · 2026-11-10 The 9.6% average portfolio yield — on the low end for BDCs — is not the problem being solved here.

What is being solved is realizations. Sponsor-backed M&A stayed subdued: direct lending volumes supporting leveraged buyouts fell roughly 21% quarter over quarter and 60% year over year. That is the LBO environment in one line, and it has a mechanical second-order effect that showed up repeatedly in the Q&A — extension asks, where sponsors prefer to hold and keep building rather than sell at today's marks. “we're absolutely in an environment where extension asks are certainly more commonplace than they have been several years ago.” — Henry Chung, Chief Investment Officer · 2026-11-10 Henry was careful to frame these as value-creation extensions rather than distress, and to note that CCAP uses them to reprice and re-underwrite, taking fees or spread where they stay and getting taken out where they do not. In a slow-exit world, the JV substitutes for the disposals the market will not hand over.

Credit: stable, but only just

The quarter's credit print was, in context, an improvement. No new nonaccruals; nonaccruals eased from 4.8% to 4.7% of debt investments at cost on the sale of a small legacy First Eagle position. But the watch list rose from 15% to 16% of fair value as 3-rated names went from 12% to 13%, while 4s and 5s fell from about 3% to 2.4%. That mix — risk migrating up the scale, not off it — is what Robert Dodd pressed on in August when he noted NAV “has been down 8 consecutive quarters now.” — Robert James Dodd, Analyst (inferred from asking questions on the call) · 2026-08-11 This quarter NAV per share moved from $17.82 to $17.72, with $0.06 of realized losses largely offset by reversing earlier unrealized marks and $0.04 of net unrealized depreciation — a rounding error by recent standards, perhaps the first real stabilization in two years.

The long term recovery posture is unchanged and deliberately unhurried: “We're not looking to fire sale any assets just to get them off the watch list.” — Henry Chung, Chief Investment Officer · 2026-11-10 That is the honest trade-off. Burning watch-list names at a discount would flatter the metric and hurt the realized return; holding them ties up capital precisely when buybacks look best. Management has chosen the slower path, and the JV is what buys them the freedom to take it.

Why this is a market story, not just a CCAP story

Buried in the prepared remarks is the connector: competition for credit is fierce even as “portions of the nontraded BDC market continue to face redemption pressure.” — Jason Breaux, Chief Executive Officer · 2026-11-10 That is a genuinely market-wide condition — the last two global keyword snapshots surfaced a redemption queue theme and persistent redemption activity across the BDC complex, an outflow story that periodically forces sellers of loans into a buyer's market. CCAP is on the receiving end of that pressure in one sense (pricing discipline is now a competitive advantage) and on the wrong end in another (a public BDC trading at a four-tenths-of-NAV discount because the structure is out of favour).

Then there is the platform. The GreenOak platform — Sun Life's consolidation of Crescent, BGO, InfraRed, SLC Fixed Income and Advisors Asset Management into roughly $326 billion of AUM — matters less for what changes at CCAP than for what does not. “as far as CCAP goes specifically, I don't anticipate any change to the investment strategy at CCAP.” — Jason Breaux, Chief Executive Officer · 2026-11-10 Of the ~$54–55 billion Crescent runs, roughly $40 billion-plus is below-investment-grade private credit; that is the origination pool the BDC can pick from once leverage is normalised, and it is the reason management can afford to sit out the current vintage.

The bottom line. CCAP has answered its most awkward shareholder question with capital rather than rhetoric — gating new loans, selling a slice of the book into a JV, and pointing the proceeds at a ~40% NAV discount, with Sun Life putting its own $25 million behind the same thresholds. The risks are equally clear: a slow-exit LBO environment that may not thaw until 2027, a watch list still drifting the wrong way, and a leverage ratio that has to fall before the buying can really begin. The stock has not noticed yet. That is either the opportunity or the warning.